Giovanni Caforio, Bristol Myers Squibb CEO (Bristol Myers)

Bris­tol My­er­s' Op­di­vo turns the boat around in Q2 as man­u­fac­tur­ing is­sues haunt CAR-T launch

What a dif­fer­ence a quar­ter can make.

Sting­ing from a dip in sales for I/O block­buster Op­di­vo last quar­ter, Bris­tol My­ers Squibb’s top check­point in­hibitor …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.